Valuation : LivaNova PLC

Market Cap 4.41B 3.78B 3.54B 3.24B 6.11B 421B 6.13B 41.96B 16.4B 212B 16.55B 16.2B 702B P/E 2026 *
20x
P/E 2027 * 24.1x
Enterprise Value 4.48B 3.85B 3.6B 3.3B 6.22B 428B 6.23B 42.67B 16.68B 216B 16.84B 16.47B 714B EV / Sales 2026 *
2.95x
EV / Sales 2027 * 2.65x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 01/03/2024
Director of Finance/CFO 56 31/10/2020
Investor Relations Contact - 01/08/2022
Director TitleAgeSince
Director/Board Member 69 19/10/2015
Chairman 74 09/06/2021
Director/Board Member 62 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.64% - - 4.41B
-2.20%-2.23%-15.11%+7.08% 193B
-2.23%-2.52%-2.26%+9.47% 115B
-2.00%+2.08%+10.56%+78.98% 61.3B
-0.25%-3.97%+26.71%+53.11% 51.37B
-1.09%+0.27%-3.72%-32.81% 51.24B
+0.37%-1.03%+16.90%-11.38% 33.69B
+0.20%+6.35% - - 30.4B
-1.09%-2.17%+40.70%-12.10% 24.36B
-0.82%+2.71%-4.04%+18.23% 23.7B
Average -0.34%-0.18%+8.72%+13.82% 64.92B
Weighted average by Cap. +0.01%-1.05%+0.21%+14.62%

Financials

2026 *2027 *
Net sales 1.52B 1.31B 1.22B 1.12B 2.11B 145B 2.12B 14.48B 5.66B 73.26B 5.71B 5.59B 242B 1.63B 1.4B 1.31B 1.2B 2.26B 156B 2.27B 15.51B 6.06B 78.47B 6.12B 5.99B 260B
Net income 226M 194M 182M 166M 314M 21.61B 315M 2.15B 842M 10.89B 849M 831M 36.04B 187M 160M 150M 138M 259M 17.85B 260M 1.78B 695M 9B 702M 687M 29.78B
Net Debt 75M 64.38M 60.27M 55.19M 104M 7.16B 104M 714M 279M 3.61B 282M 276M 11.95B -85M -72.96M -68.31M -62.55M -118M -8.12B -118M -809M -316M -4.09B -319M -312M -13.54B
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA